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SUMMARY
Introduction—The bypassing agent recombinant factor VIIa (rFVIIa) is efficacious in treating
bleeding in hemophilia patients with inhibitors. Efforts have focused on the rational engineering of
rFVIIa variants with increased hemostatic potential. One rFVIIa analog (V158D/E296V/M298Q-
FVIIa, NN1731) improves thrombin generation and clotting in purified systems, whole blood from
hemophilic patients and factor VIII-deficient mice.
Methods—We used calibrated automated thrombography and plasma clotting assays to compare
effects of bypassing agents (rFVIIa, NN1731) on hemophilic clot formation, structure, and ability
to resist fibrinolysis.
Results—Both rFVIIa and NN1731 shortened the clotting onset and increased the maximum rate
of fibrin formation and fibrin network density in hemophilic plasma clots. In the presence of tissue
plasminogen activator, both rFVIIa and NN1731 shortened the time to peak turbidity (TTPeaktPA)
and increased the area under the clot formation curve (AUCtPA). Phospholipids increased both
rFVIIa and NN1731 activity in a lipid concentration-dependent manner. Estimated geometric
mean concentrations of rFVIIa and NN1731 producing similar onset, rate, TTPeaktPA, and
AUCtPA as seen with 100% factors VIII and IX were: 24.5, 74.3, 29.7, and 37.1 nM rFVIIa, and
8.6, 31.2, 9.0, and 11.3 nM NN1731, respectively. In each case, the NN1731 concentration was
significantly lower than rFVIIa.
Conclusions—These findings suggest that like rFVIIa, NN1731 improves the formation,
structure, and stability of hemophilic clots. Higher lipid concentrations may facilitate assessment
of both rFVIIa and NN1731 activity. NN1731 appears likely to support rapid clot formation in
tissues with high endogenous fibrinolytic activity.
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INTRODUCTION
Recombinant factor VIIa (rFVIIa, NovoSeven; Novo Nordisk A/S, Copenhagen, Denmark)
is effective in treating bleeding in hemophilic patients with inhibitors.[1] At pharmacologic
doses (90–270 µg/kg, or plasma levels of 25–75 nM), rFVIIa binds to activated platelets and
increases thrombin generation on the platelet surface in a tissue factor (TF)-independent
process.[2, 3] Using in vitro assays with reconstituted model systems, hemophilic plasma,
and whole blood, we and others have shown that rFVIIa shortens the lag time and increases
the rate of thrombin generation [2, 4, 5]. Recombinant FVIIa also shortens the onset time of
fibrin formation and normalizes the structure and porosity of fibrin networks formed under
hemophilic conditions.[4, 6] Recombinant FVIIa improves fibrin formation in the presence
of tissue plasminogen activator (tPA) and plasmin[4, 5], suggesting it may improve
formation of the primary clot as well as subsequent clots if the primary clot is prematurely
lysed.
Recombinant FVIIa treatment with standard doses is effective in greater than 90% of
patients; however, clinical experience with rFVIIa suggests dosing must be individualized to
achieve optimal treatment outcomes in a subset of patients.[7, 8] Recombinant FVIIa
analogs with increased activity may promote greater thrombin generation and clot stability
than rFVIIa, and support hemostasis in these patients. Several rFVIIa analogs have been
generated that express substantially higher TF-independent activity than rFVIIa in in vitro
assays.[5, 9, 10] One of these rFVIIa analogs, NN1731, increases the thrombin generation
rate, shortens the clotting time, and increases clot stability in a purified in vitro model of
hemophilia at up to 50-fold lower concentrations than are required of rFVIIa.[5] NN1731
also dose-dependently reduces blood loss in murine tail bleeding models of hemophilia
significantly faster and at lower doses than are required of rFVIIa.[11, 12] Based on these
findings, NN1731 was recently tested in a phase I dose escalation trial in healthy males and
found to be safe and well-tolerated at doses up to 30 µg/kg (~8.4 nM).[13] A phase II trial is
now complete with good efficacy and no safety concerns observed with doses of NN1731
tested up to 80 µg/kg.[14] Given the diversity of assays to measure rFVIIa activity, it is of
interest to identify effective in vitro methods for assessing rFVIIa and NN1731 activity. It is
also of significant interest to identify concentrations of NN1731 that produce similar or
improved effects as rFVIIa, and determine whether a given concentration of either bypassing
agent similarly “corrects” all parameters of clotting (formation, structure, and stability).
In the current study we compared the effects of rFVIIa and NN1731 on the formation,
structure and fibrinolytic stability of hemophilic plasma clots. Results were compared to
100% levels of factors VIII and IX. Phospholipids increased the ability of both rFVIIa and
NN1731 to modulate hemophilic plasma clots in a concentration-dependent manner. Both
bypassing agents improved clotting, fibrin structure, and fibrinolytic resistance of lipidated
hemophilic plasma. Concentrations of rFVIIa and NN1731 were identified that produced
similar effects as 100% factor levels; in each case NN1731 exhibited significantly higher
activity than rFVIIa.
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Factor IX was purified, treated with an inhibitor mixture, isolated on Q Sepharose with
CaCl2 elution and dialyzed, as described.[4] Factor VIII (Hemofil M, Baxter) was
generously provided by Dr. Dougald M. Monroe (University of North Carolina). TPA was
from American Diagnostica (Stamford, CT, USA). RFVIIa and NN1731 (rFVIIa V158D/
E296V/M298Q) were from Novo Nordisk and were fully carboxylated at the first 9 out of
10 potential Gla positions and partially carboxylated at the 10th potential Gla position
(amino acid 35). NN1731 contains aspartate substituted for valine, valine for glutamate, and
glutamine for methionine at positions 158, 296, and 298, respectively.[9] Hemophilic
platelet-poor plasmas (PPP) from nine individuals (eight hemophilia A, one hemophilia B)
with <1% factor were purchased from HRF (Raleigh, NC, USA). TF for calibrated
automated thrombography (PRP reagent) was from Diagnostica Stago (Parsippany, NJ).
Monocytes were isolated and treated with lipopolysaccharide overnight (Serotype 0128:B12,
Sigma, St. Louis, MO, USA) to induce TF expression for clotting assays.[4] AlexaFluor-
conjugated fibrinogen was prepared as described.[15]
Phospholipid vesicles
Phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine were from Avanti
Polar Lipids (Alabaster, AL, USA). Large unilamellar vesicles (41% phosphatidylcholine /
44% phosphatidylethanolamine/15% phosphatidylserine) were made as described.[16]
Briefly, lipids were combined, dried under nitrogen gas, and resuspended in cyclohexane.
Resuspended lipids were lyophilized, resuspended in 20 mM N-2-hydroxyethylpiperazine-
N’-2-ethanesulfonic acid (HEPES) pH 7.4, 150 mM NaCl containing 1 mM ethylenediamine
tetraacetic acid, and extruded through a 0.2 µm filter ten times.
Thrombin generation
Thrombin generation was monitored in duplicate or triplicate in each experiment by
calibrated automated thrombography.[17] Briefly, TF (PRP reagent, 1 pM, final) and
phospholipids (at concentrations indicated) were added to plasmas and thrombin generation
was initiated by automatically dispensing fluorogenic substrate (Z-Gly-Gly-Arg-AMC) in
CaCl2 (416 µM and 16 mM, final, respectively). Thrombin was calibrated against wells
containing α2-macroglobulin/thrombin complex and plasma. Thrombin parameters were
calculated using Thrombinoscope software version 3.0.0.29 (Thrombinoscope BV,
Maastricht, Netherlands).
Characterization of fibrin formation and lysis
Clotting was initiated by incubating recalcified (20 mM, final) PPP with TF-bearing
monocytes (providing ~1 pM TF[18]) and phospholipids (at concentrations indicated) in the
presence or absence of tPA (1 µg/mL, final) at room temperature. RFVIIa and NN1731 were
added as indicated. Final volumes were 100 µL. Clot formation and lysis were detected by
turbidity at 405 nm with a SpectraMax 340Plus plate reader (Molecular Devices, Sunnyvale,
CA, USA). The clot formation onset was the time to the inflection point prior to the turbidity
increase. The maximum slope was the slope of a line fitted to the maximum rate of turbidity
increase (“Vmax”) using 5–10 points to determine the line. For lysis experiments, the time
to peak turbidity (TTPeaktPA) was the time to the inflection point at peak turbidity, and the
area under the curve (AUCtPA) was the sum of trapezoids formed by turbidity curves less a
baseline established by the lowest measurement taken (Kaleidagraph 4.1.0, Synergy
Software, http://www.synergy.com).
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Clots were formed as above in Labtek II glass chamber slides and scanned with a Zeiss
LSM5 Pascal confocal laser scanning microscope (Carl Zeiss, Inc) linked to a Zeiss inverted
microscope equipped with a Zeiss 63× oil immersion plan apo-chromatic lens, as described.
[15] Thirty optical sections (1024×1024 pixels) were collected at 0.36-µm intervals in the z-
axis, beginning just above the cell surface. Images were processed using 3D deconvolution
algorithms in AutoQuant’s Autodeblur software (Media Cybernetics Inc, Bethesda, MD,
USA) prior to image analysis.[15] Fibrin density (area covered by fibrin) was determined
using ImageJ 1.39t by summing individual sections to create z projections, thresholding, and
calculating the area.
Statistical analysis
Descriptive statistics for clotting onset, fibrin formation rate, fibrin density, TTPeaktPA, and
AUCtPA were summarized using graphical illustrations for mean ± standard error of the
mean (SEM) response at each concentration for rFVIIa and NN1731. Thrombin generation
peaks were analyzed by two-way analysis of variance (ANOVA) using subject and
condition as factors. A Dunnett’s post hoc test was then used to categorically identify
phospholipid concentrations that produced significantly different peaks versus no
phospholipids. For fibrin formation, network density, and lysis assays, analysis of
covariance (ANCOVA) models that controlled for hemophilia were applied to estimate the
response curves for log-transformed assay measures of rFVIIa and NN1731 relative to 100%
factors VIII and IX. The results from these models were used to estimate the geometric
mean concentrations of rFVIIa and NN1731 required to produce similar readouts as 100%
factors VIII and IX under the assumption of parallel linear assay relationships (on a log-
scale). Under the parallel assay assumption, rFVIIa is viewed as a dilution of a more potent
analog, i.e. NN1731. Relative activity of the analog versus rFVIIa was then estimated
assuming a common response rate. The 95% confidence intervals were computed using
Fieller’s method.[19, 20] A detailed Appendix describing the statistical method is available
online. A p-value < 0.05 was considered significant while a 95% confidence interval that
excludes one (zero on log-scale) was considered evidence that the analog was significantly
more active.
RESULTS
Effect of phospholipids on thrombin generation
We first titrated phospholipids (0–300 µM) into hemophilia A or B PPP, or hemophilia A or
B PPP supplemented with 50 nM rFVIIa or 5 nM NN1731. Fifty nM rFVIIa corresponds to
plasma levels of rFVIIa achieved following standard infusion of 180 µg/kg. We used 100%
factor VIII or IX (1 U/mL or 70 nM, respectively) to model “normal” (positive control) in
our experiments. Thrombin generation was initiated and measured by calibrated automated
thrombography, as described in Methods. We observed a slightly prolonged lagtime in the
absence of exogenous lipid, but otherwise little effect of phospholipid on the thrombin
lagtime under any condition (data not shown). In contrast, thrombin peak showed a
significant (p<0.0001) dependence on phospholipid concentration; compared to no added
phospholipid, 80 and 2 µM phospholipid significantly increased the thrombin peak in
hemophilic plasma (Figure 1A) and in the presence of 100% factors VIII and IX (Figure
1B), respectively. Both rFVIIa and NN1731-mediated thrombin generation in hemophilic
PPP also showed significant (p<0.0001) dependence on phospholipid concentration (Figures
1C, 1D); peaks from reactions containing ≥ 40 µM phospholipid were significantly higher
than no phospholipids for both molecules. These findings are consistent with studies of
rFVIIa-dependent thrombin generation[21, 22], but extend these observations to NN1731.
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Effect of phospholipids on clot formation
Given the dependence of both rFVIIa- and NN1731-dependent thrombin generation on
phospholipid concentration, we then determined the effects of lipid concentration on fibrin
formation. We titrated phospholipid vesicles (4–300 µM) into hemophilia A or B PPP, or
hemophilia A or B PPP supplemented with 100% factors VIII or IX, respectively, 50 nM
rFVIIa, or 5 nM NN1731, and monitored clotting by turbidity, as described in Methods.
Hemophilic samples clotted with prolonged onset and reduced maximum slope (clot
formation rate), compared to 100% factors VIII and IX (Figures 2A, 2B).[4, 5] The onset
and rate of fibrin formation in the presence or absence of factors VIII or IX were only
minimally affected by phospholipid concentrations between 4–300 µM, whereas the onset
and rate of rFVIIa- and NN1731-dependent fibrin formation were progressively shortened
and increased, respectively, by additional phospholipid. Discord between the thrombin
generation lagtime and clot formation onset is thought to reflect differences in the sensitivity
of assay parameters to extrinsic and intrinsic activity, as well as differences in using
thrombin chromogenic or fluorogenic activity versus thrombin conversion of fibrinogen to
fibrin as an assay readout.[23] In particular, fibrinogen conversion reflects a thrombin
concentration threshold phenomenon; lower concentrations of thrombin can convert
fibrinogen to fibrin than can be detected by thrombin substrates. Because 125 µM
phospholipid was the lowest phospholipid concentration that produced a similar fibrin
polymerization rate in rFVIIa-treated samples as 100% factors VIII and IX, this
phospholipid concentration was used in subsequent clotting studies.
Effect of rFVIIa and NN1731 on clotting
We next followed fibrin formation in hemophilic PPP supplemented with 125 µM
phospholipids and rFVIIa (1–300 nM) or NN1731 (0.5–25 nM) (Figure 3). Addition of
either rFVIIa or NN1731 to lipidated hemophilic plasma significantly (p<0.05) shortened
the onset (Figure 3B) and increased the rate (Figure 3C) of fibrin formation in a
concentration-dependent manner (Table I). From these data we determined the estimated
geometric mean concentrations of rFVIIa and NN1731 that produced similar clotting onset
and rate as 100% factors VIII/IX (Table I), and used these data to calculate the relative
potency of NN1731 compared to rFVIIa (Table II).
Effect of rFVIIa and NN1731 on fibrin structure
Growing evidence suggests fibrin structure is a sensitive reflection of thrombin levels
present during fibrin formation and an integral determinant of the clot’s mechanical and
fibrinolytic stability.[24] Clots formed from hemophilic plasma and whole blood exhibit an
abnormally coarse, porous network of thick fibers compared to normal, and rFVIIa increases
fibrin network density.[4, 6] A recent preliminary report suggested NN1731 can similarly
decrease fibrin network porosity of hemophilic clots.[25] Herein we tested a broader range
of rFVIIa and NN1731 concentrations to compare the dose-dependency of rFVIIa and
NN1731 on network density (Figure 4A). Our data (Table I, Figure 4B) are consistent with
the prior report, but suggest considerable variability with density measurements; the wide
confidence intervals reflect inter-individual differences in plasma activity, variability in
network structure, and fewer replicates due to the time consuming nature of these
assessments. Consistent with previous findings[4], fibers present in hemophilic clots
appeared thicker than those formed in the presence of 100% factors VIII and IX. However,
because fiber diameter (~200–400 nm) is at the lower resolution limit of LSCM[26, 27], we
did not specifically quantify fibrin diameter in these clots.
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Effect of rFVIIa and NN1731 on fibrinolysis
It has been proposed that delayed bleeding in hemophilic patients results, at least in part,
from increased susceptibility of hemophilic clots to premature fibrinolysis.[28] We
examined the ability of rFVIIa and NN1731 to improve fibrin formation and stability in the
presence of tPA. As shown in Figure 5, clot formation (turbidity increase) and subsequent
lysis (turbidity decrease) are observed in the presence of 100% factors VIII and IX levels;
however, hemophilic conditions are not sufficiently procoagulant to produce fibrin. Both
rFVIIa and NN1731 significantly (p<0.05) shortened the TTPeaktPA (peak incorporation of
fibrin into the clot, Figure 5B) and AUCtPA (clot stability, Figure 5C); however, the
estimated geometric mean concentrations of NN1731 required were lower than those of
rFVIIa (Table I). These findings are consistent with increased procoagulant activity of
NN1731 relative to rFVIIa (Table II).
DISCUSSION
Since the introduction of rFVIIa as a bypassing agent for treating bleeds in hemophilic
patients with inhibitors, considerable effort has focused on developing improved variants of
this molecule. The need for these improvements stems, in part, from observations that
rFVIIa dosing must be individualized in certain patients to achieve optimal treatment
outcomes.[7, 8] Molecules currently in basic and clinical development include a factor VIIa-
albumin fusion protein (“rVIIa-FP”)[29], factor VIIa formulated with PEGylated
liposomes[30], GlycoPEGylated rFVIIa[31], and recombinant analogs of [rFVIIa-QE[32]
rFVIIa(VEAY)[33], and NN1731[5, 9, 11, 12, 34–37]]. NN1731, in particular, has been
evaluated in purified systems[36], cell-based reconstituted models of hemophilia[5],
hemophilic whole blood[34, 35], and in vivo studies in hemophilic mice[11, 12] and
dogs[37, 38]. These studies have suggested NN1731 induces hemostasis in hemophilic
conditions, but with a faster onset and at lower concentrations than are required of rFVIIa.
Our current study using lipidated plasma from individual hemophilic patients supports and
extends these observations on the mechanism of action of rFVIIa and NN1731. We
identified rFVIIa and NN1731 estimated geometric mean concentrations that produced
similar effects as 100% factor VIII and IX on the onset and formation rate of hemophilic
clots (Figure 3), fibrin network structure (Figure 4), and resistance to fibrinolysis (Figure 5).
In each of these assays, NN1731 demonstrated at least 2.4-fold higher fibrin-promoting
activity than rFVIIa (Table II).
Dosing in the initial in vivo rFVIIa studies was based on theoretical calculations of the
rFVIIa concentration needed to saturate TF at injury sites; however, studies showing that
rFVIIa functions via binding to the platelet surface[2] provide a rationale for the
supraphysiologic doses necessary to achieve efficacy in patients.[39] It has been notoriously
difficult to identify an in vitro assay in which rFVIIa has similar effects as 100% factor VIII
and IX levels. While thrombin generation assays are sensitive to rFVIIa activity, studies
evaluating thrombin generation have not shown normalization by rFVIIa.[4, 5, 34, 40, 41] It
is therefore of considerable interest that our clotting assays demonstrated several parameters
in which rFVIIa produces similar effects as 100% factor VIII and IX levels. Specifically,
under the conditions of our assays, the estimated geometric mean rFVIIa concentrations
producing similar readouts as 100% factors VIII and IX for onset and rate in the clot
formation assays, and TTPeaktPA and AUCtPA in the fibrinolysis assays were 24.5, 74.3,
29.7, and 37.1 nM, respectively (Table I). Additional repeated measures ANCOVA models
were explored to account for potential dependence of measures of clot formation and
fibrinolysis within an assay, but these models did not produce appreciably different
estimates from those in Tables I and II. Interestingly, for both models, these concentrations
are close to the expected plasma concentrations achieved following a dose of 90 µg/kg
rFVIIa (~25 nM), which is efficacious in 70–90% of patients.[42] These data suggest the
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conditions currently used for most thrombin generation tests might be further optimized to
provide the best readout for identifying clinically-effective bypassing agent concentrations.
Further studies are warranted to determine whether this lipidated plasma-based clotting
assay can be used to predict dosing to induce hemostasis in hemophilic patients.
Although it is probably ideal to measure rFVIIa activity in the presence of platelets,
logistical difficulties in collecting and handling platelet-rich plasma have prevented the
wide-spread adoption of this approach in laboratory assays. Synthetic phospholipid vesicles
can be substituted for platelets in thrombin generation assays, and recent studies have shown
that in the absence of platelets, exogenous phospholipids are essential for rFVIIa-mediated
thrombin generation.[21, 22, 43] We extended these findings to show NN1731 also produces
shorter onsets and increased clot formation rates with increasing phospholipids (Figure 2).
Thus, although platelets are the physiologic site of rFVIIa activity in hemophilia,
phospholipid vesicles with similar phosphatidylserine content as platelets[44] such as those
used in this study, may be a practical and effective substitute in preclinical dosing studies to
screen other novel factor VIIa variants. Since we and others[21, 22] have shown both
thrombin generation and clot formation are phospholipid concentration-dependent, the lipid
concentrations used in these assays should be optimized for these assessments. Of course,
since the response to rFVIIa has been proposed to stem, in part, from the quality of the
endogenous platelet population in patients[1, 45], a “normalizing” concentration of rFVIIa
or NN1731 in assays utilizing lipidated PPP may not reflect doses needed to achieve
efficacy in “non-responder” patients. In these cases, performing in vitro clotting assays with
platelet-rich plasma may provide more tailored information on dosing than assays using
phospholipids.
In conclusion, our data show the significant dependence of thrombin generation and fibrin
formation on phospholipid concentration, and suggest that optimizing the lipid concentration
may provide clinically-relevant information about bypass factor dosing. Both rFVIIa and
NN1731 significantly improve fibrin formation, structure and stability in hemophilic clots;
however, effects of NN1731 manifest at significantly lower concentrations than are required
of rFVIIa. Finally, our findings suggest NN1731 will have clinical utility as a hemostatic
agent in hemophilic inhibitor patients refractory to standard rFVIIa concentrations. These
data support continued evaluation of this agent in in vitro and in vivo studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Like rFVIIa, NN1731-dependent thrombin generation depends on the phospholipid
concentration
Thrombin generation was initiated by incubating re-calcified plasmas with 1 pM TF and
phospholipids at the concentrations indicated. Plasmas from eight different hemophilia A
patients were tested, not all donors were tested at all conditions. Graphs show thrombin
peaks (±SD) in hemophilia PPP (A), or hemophilia A PPP supplemented with 100% factor
VIII (B), 50 nM rFVIIa (C) or 5 nM NN1731 (D), for 5–8 trials at each concentration.
*p<0.05, **p<0.0001
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Figure 2. Both rFVIIa and NN1731 shorten the onset and increase rate of clot formation in a
phospholipid-dependent manner
Clotting was initiated by incubating re-calcified hemophilic PPP with phospholipids and TF-
bearing monocytes, in the presence of 100% factors VIII/IX, 50 nM rFVIIa, 5 nM NN1731,
or buffer. Plasmas from six hemophilic patients were tested (five hemophilia A and one
hemophilia B). Clot formation was monitored by turbidity at 405 nm. A) Onset and B) Rate
of clot formation (±SEM). In experiments where samples did not clot, the onset was
assigned to the final time point recorded (120 minutes). Symbols are: Hemophilia (open
circles), 100% factors VIII/IX (closed circles), 50 nM rFVIIa (open triangles), 5 nM
NN1731 (closed triangles).
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Figure 3. Compared to rFVIIa, lower concentrations of NN1731 shorten the onset and increase
the rate of clot formation
Clotting was initiated by incubating re-calcified plasma with 125 µM phospholipids and TF-
bearing monocytes and monitored by turbidity at 405 nm. A) Clot formation from a single
experiment, representative of separate experiments with six plasma donors (five hemophilia
A, one hemophilia B). Symbols for panel A are indicated in the inset. B) Onset and C) Rate
of clot formation from 1–23 clots at each condition (±SEM). Symbols for B and C are:
Hemophilia (open circle), 100% factors VIII/IX (closed circle), rFVIIa (open triangles),
NN1731 (closed triangles).
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Figure 4. Compared to rFVIIa, lower concentrations of NN1731 increased fibrin network density
Clotting was initiated by incubating re-calcified plasma with 125 µM phospholipids and TF-
bearing monocytes in Labtek II glass chamber slides. Laser scanning confocal microscopy
was performed as described in Methods. A) Confocal micrographs (z-projections of 30
individual slices) of clots formed in hemophilia PPP, or hemophilia PPP supplemented with
100% factors VIII/IX, rFVIIa, or NN1731. Images are from a single experiment,
representative of experiments with six hemophilia patients (five hemophilia A, one
hemophilia B). B) Fiber density (arbitrary units, A.U. ±SEM) of 2–19 clots at each
concentration. Symbols for panel B are: Hemophilia (open circle), 100% factors VIII/IX
(closed circle), rFVIIa (open triangles), NN1731 (closed triangles).
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Figure 5. NN1731 improved resistance to fibrinolysis at lower concentrations than were required
of rFVIIa
Clotting was initiated by incubating re-calcified hemophilic PPP with TF-bearing
monocytes, 125 µM phospholipids, and 1 µg/mL tPA. Clot formation (turbidity increase)
and clot lysis (turbidity decrease) were monitored at 405 nm. A) Fibrin formation and lysis
from a single experiment, representative of experiments with six different plasma donors
(five hemophilia A, one hemophilia B). Symbols for panel A are indicated in the inset. B)
Time to peak of turbidity. In experiments where samples did not clot, the time to peak was
assigned to the final time point recorded (60 minutes). C) Area under the curve (±SEM)
using 3–11 clots at each condition were normalized with “100% factor” equal to 1 for each
experiment. Symbols for B and C are: Hemophilia (open circle), 100% factors VIII/IX
(closed circle), rFVIIa (open triangles), NN1731 (closed triangles).
Gray et al. Page 15

























Gray et al. Page 16
TABLE I
Estimated Geometric Mean Concentrations Indistinguishable from 100% Factors VIII and IX.
Assay Parameter nM rFVIIa (95% CI) nM NN1731 (95% CI)
Clot Formation and Structure
Onset 24.5 (12.2–50.1) 8.6 (4.1–19.8)
Formation Rate 74.3 (34.7–183.1) 31.2 (13.1–96.7)
Fibrin Density 34.5 (3.1–172.5) 2.9 (0.32–22.3)
Fibrinolysis
Time to Peak Turbidity 29.7 (14.8–61.9) 9.0 (4.5–19.3)
Area Under Curve 37.1 (5.0–467.1) 11.3 (1.7–182.5)
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TABLE II
Relative Activity of NN1731 versus rFVIIa
Assay Clot Parameter Relative Increased Activity (95% CI)
Clot Formation and Structure
Onset 2.9 (1.4–5.2)
Formation Rate 2.4 (1.1–4.6)
Fibrin Density 12.1 (1.0–76.9)
Fibrinolysis
Time to Peak Turbidity 3.3 (2.0–5.2)
Area Under Curve 3.3 (0.6–12.7)
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